查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571501

NUT 中线癌症治疗市场规模、份额和趋势分析报告：2024-2030 年按治疗、给药途径、最终用途、地区和细分市场进行的预测

NUT Midline Carcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy), By Route Of Administration (Oral), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

NUT 中线癌症治疗市场成长与趋势：

Grand View Research, Inc.的研究报告显示，到2030年，全球NUT中线癌症治疗市场规模预计将达到441亿美元，复合年增长率为12.4%。

这一显着增长主要是由于对罕见癌症类型的认识提高、标靶治疗的进步以及对精准医疗的日益关注。诊断工具的进步和医疗保健专业人员意识的提高使得更多病例能够更早被发现，从而导致对有效治疗的需求增加。

标靶治疗的兴起，特别是那些关注表观遗传机制的治疗，对于这个市场至关重要。例如，针对通常与 NMC 相关的 BRD4-NUT 融合蛋白的 BET（Bromodomain和末端外）抑制剂的开发开闢了新的治疗途径。百时美施贵宝等公司处于这项研究的前沿，开发了 trotabresib (CC-90010) 等药物，目前正处于临床试验阶段。由于这种疾病的侵袭性和预后不良，因此迫切需要开发新的治疗方法。这种疾病的罕见性也带来了挑战，包括临床试验的患者数量有限以及缺乏全面的流行病学资料。

政府和监管机构在加速 NMC 治疗开发方面也发挥着重要作用。在包括美国和欧洲在内的许多地区，NMC 已被指定为一种罕见疾病，为开发这种罕见癌症治疗方法的公司提供税额扣抵和扩大市场独占权等奖励。这些激励措施对于鼓励 NMC 研究投资至关重要，因为 NMC 研究受到患者数量较少的限制。

NUT 中线癌症治疗市场报告亮点

  • 2023年，化疗市场在NUT中线癌症治疗市场中占最大收益占有率，达32.5%。
  • 2023年，静脉注射细分市场将占最大收益占有率，达68.7%。这是由于 NMC 管理中对速效治疗的需求所驱动的，因为更高的生物有效性和更快地将药物输送到血液中可确保有效的治疗方法到达癌细胞。比口服药物更有效。
  • 预计专科诊所在预测期内的复合年增长率将达到 13.5%。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章 NUT 中线癌症治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场成长要素分析
    • 市场限制因素分析
  • NUT 中线癌症治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 NUT 中线癌症治疗市场：按治疗分类的估计和趋势分析

  • 全球 NUT 中线癌症治疗市场：依治疗分类 - 仪表板
  • 全球 NUT 中线癌症治疗市场：依治疗分类 - 波动分析
  • 全球 NUT 中线癌症治疗市场：依治疗分类-收益
  • 化疗
  • 标靶治疗
  • 免疫疗法
  • 放射治疗
  • 其他的

第五章 NUT 中线癌症治疗市场：依给药途径估计与趋势分析

  • 全球 NUT 中线癌症治疗市场：按给药途径- 仪表板
  • 全球 NUT 中线癌症治疗市场：依给药途径- 变异分析
  • 全球 NUT 中线癌症治疗市场：按给药途径- 收益
  • 口服
  • 静脉
  • 其他的

第六章 NUT 中线癌症治疗市场：按最终用途分类的估计和趋势分析

  • 全球 NUT 中线癌症治疗市场：依最终用途分类 - 仪表板
  • 全球 NUT 中线癌症治疗市场：依最终用途 - 变化分析
  • 全球 NUT 中线癌症治疗市场：依最终用途分类-收益
  • 医院
  • 专科诊所
  • 其他的

第7章 NUT中线癌症治疗市场：区域估计与趋势分析

  • 按地区 - 仪表板
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 2023年主要企业市场占有率分析
    • Merck &Co. Inc
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • C4 Therapeutics, Inc.
    • Ipsen Biopharmaceuticals, Inc
    • GSK plc
Product Code: GVR-4-68040-444-7

NUT Midline Carcinoma Treatment Market Growth & Trends:

The global NUT midline carcinoma treatment market size is anticipated to reach USD 44.1 billion by 2030, growing at a CAGR of 12.4%, according to a report by Grand View Research, Inc. This significant growth is majorly driven by the increasing awareness of rare cancer types, advancements in targeted therapies, and the growing focus on precision medicine. With advancements in diagnostic tools and greater awareness among healthcare professionals, more cases are being identified earlier, leading to an increased demand for effective treatments.

The rise of targeted therapies, particularly those focusing on epigenetic mechanisms, has been pivotal in this market. For instance, the development of BET (bromodomain and extra-terminal) inhibitors, which target the BRD4-NUT fusion protein commonly associated with NMC, has opened new avenues for treatment. Companies such as Bristol-Myers Squibb are at the forefront of this research, developing drugs such as Trotabresib (CC-90010), which are currently in clinical trials. The aggressive nature of the disease and the poor prognosis associated with it create a strong imperative for the development of new therapies. The rarity of the disease also presents challenges, including limited patient pools for clinical trials and a lack of comprehensive epidemiological data.

Government and regulatory bodies are also playing a crucial role in accelerating the development of NMC treatments. In many regions, including the U.S. and Europe, NMC has been granted orphan disease status, providing incentives such as tax credits and extended market exclusivity to companies developing treatments for this rare cancer. These incentives are critical in encouraging investment in NMC research, which is otherwise limited due to the small patient population.

NUT Midline Carcinoma Treatment Market Report Highlights:

  • In 2023, the chemotherapy segment accounted for the largest revenue share of 32.5% in NUT midline carcinoma treatment market.
  • The intravenous segment accounts for the largest revenue share of 68.7% in 2023 driven by the need for fast-acting treatments in managing NMC due to its higher bioavailability and quicker delivery of the drug to the bloodstream, ensuring that the potent therapies reach the tumor cells more effectively than oral medications might.
  • Specialty clinics are anticipated to achieve the highest CAGR of 13.5% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Route of Administration
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. End Use
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. NUT midline carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence NUT Midline Carcinoma
      • 3.2.1.2. Advancement in Diagnostics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Diagnostic Challenges
      • 3.2.2.2. Limited Awareness
  • 3.3. NUT midline carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. NUT midline carcinoma Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global NUT midline carcinoma Treatment Market: Treatment Dashboard
  • 4.2. Global NUT midline carcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global NUT midline carcinoma Treatment Market by Treatment, Revenue
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Targeted Therapy
    • 4.5.1. Targeted Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Radiation Therapy
    • 4.7.1. Radiation Therapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. NUT midline carcinoma Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global NUT midline carcinoma Treatment Market: Route of Administration Dashboard
  • 5.2. Global NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
  • 5.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Intravenous
    • 5.5.1. Intravenous market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. NUT midline carcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 6.1. Global NUT midline carcinoma Treatment Market: End Use Dashboard
  • 6.2. Global NUT midline carcinoma Treatment Market: End Use Movement Analysis
  • 6.3. Global NUT midline carcinoma Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Specialty Clinics
    • 6.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other
    • 6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. NUT midline carcinoma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. Merck & Co. Inc
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bristol-Myers Squibb Company
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Pfizer Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. F. Hoffmann-La Roche Ltd
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. C4 Therapeutics, Inc.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Ipsen Biopharmaceuticals, Inc
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. GSK plc
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 4 North America NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 North America NUT Midline Carcinoma Treatment Market, End Use, 2018 - 2030 (USD Million)
  • Table 6 U.S. NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9 Canada NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 Canada NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12 Mexico NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 13 Mexico NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15 Europe NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 16 Europe NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Europe NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 19 Germany NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 20 Germany NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Germany NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 22 UK NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 UK NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 25 France NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 26 France NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 France NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 28 Italy NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Italy NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Italy NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 31 Spain NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 32 Spain NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 34 Denmark NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 35 Denmark NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 37 Sweden NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 Sweden NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Sweden NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40 Norway NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 41 Norway NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Norway NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 47 China NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 48 China NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 China NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 50 Japan NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Japan NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Japan NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 53 India NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 54 India NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 India NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 56 South Korea NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 57 South Korea NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Korea NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 59 Australia NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 Australia NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Australia NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 62 Thailand NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 63 Thailand NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Thailand NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65 Latin America NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 66 Latin America NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 67 Latin America NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Latin America NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 69 Brazil NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 70 Brazil NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Brazil NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 72 Argentina NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Argentina NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 75 MEA NUT Midline Carcinoma Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 76 MEA NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 77 MEA NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 MEA NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 79 South Africa NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 South Africa NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 85 UAE NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 UAE NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)
  • Table 88 Kuwait NUT Midline Carcinoma Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait NUT Midline Carcinoma Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Kuwait NUT Midline Carcinoma Treatment Market, By End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 NUT midline carcinoma Treatment Market: Market Outlook
  • Fig. 14 NUT midline carcinoma Treatment Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 NUT midline carcinoma Treatment Market Driver Impact
  • Fig. 18 NUT midline carcinoma Treatment Market Restraint Impact
  • Fig. 19 NUT midline carcinoma Treatment Market Strategic Initiatives Analysis
  • Fig. 20 NUT midline carcinoma Treatment Market: Treatment Movement Analysis
  • Fig. 21 NUT midline carcinoma Treatment Market: Treatment Outlook and Key Takeaways
  • Fig. 22 Chemotherapy market estimates and forecast, 2018 - 2030
  • Fig. 23 Targeted therapy market estimates and forecast, 2018 - 2030
  • Fig. 24 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 25 Radiation therapy market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 NUT midline carcinoma Treatment Market: Route of Administration Movement Analysis
  • Fig. 28 NUT midline carcinoma Treatment Market: Route of Administration Outlook and Key Takeaways
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030
  • Fig. 30 Intravenous market estimates and forecast, 2018 - 2030
  • Fig. 31 Other market estimates and forecast, 2018 - 2030
  • Fig. 32 NUT midline carcinoma Treatment Market: End Use Movement Analysis
  • Fig. 33 NUT midline carcinoma Treatment Market: End Use Outlook and Key Takeaways
  • Fig. 34 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 35 Specialty clinics market estimates and forecast, 2018 - 2030
  • Fig. 36 Other market estimates and forecast, 2018 - 2030
  • Fig. 37 Global NUT midline carcinoma Treatment Market: Regional Movement Analysis
  • Fig. 38 Global NUT midline carcinoma Treatment Market: Regional Outlook and Key Takeaways
  • Fig. 39 Global NUT midline carcinoma Treatment market share and leading players
  • Fig. 40 North America, by country
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Mexico key country dynamics
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Market share of key market players- NUT midline carcinoma Treatment market